Tohoku University Technology:Candidate of therapeutic drug for muscular dystrophy: T16-108
Metformin helps to repair skeletal muscle!
During sarcolemma repair process, dysferlin protein accumulates at injury part. Dysferlin gene mutation is found in dysferlinopathy, which is a type of muscular dystrophy. Inventors have shown that AMPK, which regulates energy metabolism, binds membrane repair protein dysferlin. Administration of metformin, one of the AMPK activator, improves cell membrane repair in dysferlinopathy. This invention proposes to use metformin, well known therapeutic drug for diabete, as an activator of sarcolemma repair, and to use it as a therapeutic drug for muscular disease such as muscular dystrophy and various diseases that present cell membrane fragility.
Inquire About This Product
basic information
For details, please contact us or refer to the PDF.
Price range
Delivery Time
Applications/Examples of results
For details, please contact us or refer to the PDF.
catalog（1）
Download All Catalogs
Company information
The revenue generated from technology transfer is reinvested into universities and researchers as new research funding, which is used to create further research outcomes. To ensure the smooth operation of this cycle, known as the "Intellectual Creation Cycle," we will actively promote technology transfer. The types of seeds we handle include patents, know-how, databases, and programs. We have established a collaborative framework by concluding basic technology transfer agreements with the following universities (as of June 1, 2025): - Tohoku University - Hirosaki University - Iwate University - Akita University - Fukushima University - Yamagata University - Tohoku Gakuin University - Iwate Medical University - Fukushima Medical University - Aizu University - Miyagi University - Hokkaido University - Muroran Institute of Technology - Showa Medical University
